Project Grant R01DA065290
Award Date 9/15/26
Completion Date 7/31/31
Dollars Obligated $982K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Belmont, MA 02478, USA
Similar Awards
- The National Institute on Drug Abuse awarded The McLean Hospital Corporation $736,811 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal cohort study of opioid use disorder. The project characterizes the long-term course of opioid use disorder through remote follow-up of 550 adults with opioid use disorder recruited from sites across the United States. The study employs monthly patient-reported outcomes and annual...
- The National Institute on Drug Abuse awarded McLean Hospital $907,308 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate Recovery Inspired Support Engagement (RISE), an evidence-based intervention targeting support persons of individuals with substance use disorders during transitions from inpatient and residential treatment to community settings. The project addresses a gap in substance use treatment by centering intervention on support...
- The National Institute on Drug Abuse awarded The McLean Hospital Corporation $451,000 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a biometrics-based platform using machine learning to predict relapse in individuals with opioid use disorder. The project will integrate data from physiological, behavioral, and subjective mood state measurements captured by wearable biosensors to create algorithms that detect early warning signs of opioid craving...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (Massachusetts General Hospital) $453,750 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026. The award funds a mixed-methods examination of adolescent overdose and return to high-risk drug use after inpatient addiction treatment. The research leverages an existing longitudinal dataset of adolescents aged 12–19 followed for 12 months after treatment discharge, 52 percent of whom...
- The National Institute on Drug Abuse awarded The McLean Hospital Corporation $194,206 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research identifying individual clinical and environmental predictors of buprenorphine response in patients with opioid use disorder. The project will harmonize data from five clinical trials on buprenorphine maintenance (N=1,439) to determine which patient characteristics predict treatment response at the individual...
- The National Institute on Drug Abuse awarded Boston Children's Hospital $800,131 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the functions and mechanisms of a molecularly defined prefrontal cortex neuron subtype in drug addiction. The research focuses on identifying and characterizing POU3F1-expressing layer 5 neurons in the prefrontal cortex and their role in regulating cocaine-seeking behavior. The work employs single-cell RNA sequencing...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $870,407 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on pre-release Medicaid effects on youth experiences related to substances (PRIME Years). The project addresses barriers to behavioral health service access for youth ages 16–25 following incarceration, a population with 36–84% prevalence of substance use history. The research examines Medicaid...
- The National Institute on Drug Abuse awarded Arizona State University $314,000 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct secondary data analysis applying mediation mixture modeling and machine learning to identify heterogeneous risk pathways leading to youth substance use initiation. The project uses the Adolescent Brain Cognitive Development (ABCD) Study, a national longitudinal dataset tracking youths' behavioral health, to examine...
- The National Institute on Drug Abuse awarded Trustees of Boston University $193,751 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a career development research initiative examining quality of care in outpatient substance use disorder treatment facilities. The award funds a five-year training and research plan designed to develop the principal investigator as an independent substance use disorder services researcher. The research uses a novel...
- The National Institute on Drug Abuse awarded the Lieber Institute Inc. $1.855 million on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop three-dimensional cellular resolution spatio-molecular maps of the human nucleus accumbens across its anterior-posterior axis. The nucleus accumbens is a key node in the brain's reward circuitry, and perturbations in reward signaling are implicated in substance use disorders. The project extends prior spatial...